Intrabiotics (936085)-- Es tut sich was - 500 Beiträge pro Seite

[DieBesten]

Wenn wir Heute über 2 Dollar schließen,
wird es erst mal Richtung Norden gehen.

Gruß DieBesten

[DieBesten]

Ich sag´s ja sie wird explodieren.
Sind vielleicht news in anmarsch?

[js200]

Die News sind schon länger da :

PR Newswire, 11/07/2001 08:02

IntraBiotics Announces Start of Phase III Trial of Iseganan For Oral Mucositis

/FROM PR NEWSWIRE SAN FRANCISCO 415-543-7800/ [STK] IBPI [IN] BIO MTC [SU] PDT TO BUSINESS AND MEDICAL EDITORS:

IntraBiotics Announces Start of Phase III Trial of Iseganan

For Oral Mucositis

MOUNTAIN VIEW, Calif., Nov. 7 /PRNewswire/ -- IntraBiotics Pharmaceuticals, Inc. (NASDAQ:IBPI), a biopharmaceutical company engaged in the development of novel antibiotics, today announced that it has begun patient enrollment in the third and last planned pivotal Phase III trial of its iseganan antibiotic to reduce the incidence and severity of oral mucositis, a painful and debilitating condition resulting from the treatment of cancer. The purpose of this trial in high-dose chemotherapy patients is to further demonstrate the efficacy benefits and safety profile of the product. A Phase II and a Phase III trial of iseganan HCl oral rinse have been completed in this high-dose chemotherapy patient population, and a second Phase III trial in patients undergoing radiotherapy for head and neck cancer is currently underway

Dr. Frank Giles, M.D., Chairman of the Study Steering Committee and a Director of New Therapeutics Research at the M.D. Anderson Cancer Center, Houston, Texas said, "This is very important study as there is no currently effective treatment available for oral mucositis. The previous studies have shown that iseganan is effective across many study endpoints, including visual inspection, reduction in pain, and ability to function or swallow and that the drug is well tolerated. We are very pleased to be the first site to enroll a patient in this pivotal trial."

The Company plans to enroll approximately 500 patients in this randomized, double blind, placebo controlled study at approximately 30 cancer centers in the United States in the coming year. This new trial was designed based on the results of a previous Phase III trial presented in May, 2001, which was damaged by a contractor`s error so as to underestimate the benefit of the drug as measured by a primary and several secondary endpoints. In the damaged trial, the product met certain secondary endpoints with respect to efficacy but failed to meet its primary endpoint. Consequently, IntraBiotics announced its intention to repeat a study in this patient population with enhancements based on the results and lessons of the first trial. The eligible patients are those undergoing either high-dose myeloablative chemotherapy with a bone marrow or peripheral blood stem cell transplant or patients receiving high dose chemotherapy for the treatment of leukemia. In these cases, the incidence and severity of oral mucositis are particularly high.

Dr. Henry Fuchs, M.D., Vice President Clinical Affairs at IntraBiotics explained, "The first Phase III trial in high dose chemotherapy trial was damaged by a contractor who mixed up active and placebo doses for 102 out of 323 patients. The impact of the error was profound. The trial was damaged and not useful for registration of the drug. Most importantly though the drug appears to be effective in reducing the incidence, severity and sequelae of oral mucositis, several endpoints of the clinical trial, including measures of disease severity, pain and ability to swallow did meet statistical significance. The benefits of the drug were very likely underestimated based on the mixing of active and placebo medication in nearly one third of the patients. This new trial will hopefully disclose the full benefit and support registration of the product. We hope to enroll and complete the data analysis of this trial by next November. "

Dr. Giles concurred, "Having participated in the first and damaged Phase III trial for this product, I am very enthusiastic about participating in this `repeat` trial. Given our unfortunate luck in the first trial, the Company and the Steering Committee have designed this trial to have a high statistical power of greater than 85% of hitting the primary endpoint of reducing disease severity. Many of the sites including our own are now very experienced with the product and trial and expect enrollment to go very smoothly."

The Company is also conducting an additional Phase III trial for iseganan HCl oral rinse in patients undergoing radiotherapy for head and neck cancers and likely to experience oral mucositis. Oral mucositis resulting from chemotherapy and radiotherapy are quite similar. The Company`s intent is to derive a relatively broad label claim if Phase III trials in each population are ultimately successful. The radiotherapy trial is currently enrolling patients on schedule at 50 sites in the United States and Europe. Full enrollment of all 530 patients is expected to conclude in the fourth quarter, 2001 and data is expected in the second quarter, 2002.

IntraBiotics Pharmaceuticals, Inc., founded in 1994, is a biopharmaceutical company engaged in the development of novel antibacterial and antifungal drugs for the treatment and prevention of serious infectious diseases, including those caused by multi-drug resistant pathogens. The Company plans to continue to build product line extensions through new formulations and new indications for its products that have progressed beyond Phase I. IntraBiotics` product portfolio includes iseganan HCI oral solution for ventilator-associated pneumonia (at phase II), iseganan aerosol for cystic fibrosis lung infections (at phase II), and ramoplanin topical for staphylococcal infections (at phase II). Additional information is available at the Company`s web site: www.intrabiotics.com.

Certain statements in this press release contain forward-looking information and are subject to risks and uncertainties, such as statements regarding product development, clinical developments and projections of future expenses. As such, they are subject to the occurrence of many events outside of IntraBiotics` control and are subject to various risk factors that could cause IntraBiotics` results to differ materially from those expressed in any forward-looking statement. The risk factors include, without limitation, the inherent risks of product development failure; uncertainty of the timing, cost, extent and results of clinical trials; risk of delays in conducting clinical trials due to factors such as slower than expected rate of patient recruitment, additional regulatory requests, inability to manufacture sufficient quantities of materials used for clinical trials, difficulties with clinical supplies or unforeseen safety issues; the Company`s ability to raise capital through private or public financings when needed or on favorable terms; regulatory risks, and risks related to proprietary rights, market acceptance and competition. These risk factors are more fully described in documents on file with the Securities and Exchange Commission including, but not limited to, our Annual Report on Form 10-K, as amended, for the year ended December 31, 2000 and on Form 10-Q, for the quarter ended June 30, 2001.


JS200

[js200]

Die 2,00$ wurden gehalten, sieht sehr gut aus.

Technich kein Problem bis 3,5 $ ( 200ter Tageslinie )

75% problemlos ( 1 Monat )

Strong buy

Endovasc ( BB:ENDV ) auch interessant

Strong buy

JS200

[DieBesten]

Ich kann mich natürlich täuschen,
aber ich glaube sie ist kurz vor einer Explosion.
Wünsche allen investierten einen grünen Wochenausklang.

Gruß DieBesten

[js200]

Sie kommt und geht.

@ die Besten

Ist auch meine Meinung von einem Ausbruch.

Wenn man die Charts von Consors ansieht, steht die 200ter Tageslinie bei 2,05 $ (Rückzug normal)

Bei technical-investor bei um die 3$(Rückzug nicht normal)

Welche ist richtig???

JS200

[DieBesten]

Der Kampf (Krampf) um die 2 Dollar.
Mit etwas Glück sehen wir ab heute Abend
keine Kurse mehr unter 2 Dollar!

Gruß DieBesten

[js200]

2,17 $ ist doch nicht schlecht : ODER ?????

Sieht sehr gut aus, alles positiv

Strong buy

@Die Besten,
schau mal die Aktie ENDOVASK an OTC ENDV
macht ebenfalls eine Flagge
(Potential bis schätzungsweise 0,7$ ist ein kleiner Zock Wert, soll keine Kaufempfehlung sein, aber man weiss ja nie)
Ich bin investiert und kaufe nach.

Strong buy

JS200

[DieBesten]

@js200
Könntest recht haben mit deinem tipp.
Habe im Moment aber kein Geld zum Zocken frei.
Werde den Wert weiter beobachten.

Gehe davon aus das wir bis ende nächster Woche
die 3 Dollar hinter uns lassen könnten.
Was meinst Du?

Gruß DieBesten

[DieBesten]

@js200
Hatte ich noch vergessen.
Die 200er Tagelinie ist bei 2,05$.

[js200]

@ die Besten

Sieh dir den Chart bei Investtech.com an, ich erkenne einen kleinen Widerstand bei 2,3 bis 2,5$, der nächste befindet sich bei 5,2 bis 5,5$

Sollte die Tests (III) nicht wieder gestoppt werden, könnte man von der Wertschätzung von Lehman Brothers (25$)ausgehen.

Das heisst : ab heute 1000% innerhalb 1 Jahr ?????

Mein 12 Monatsziel liegt bei maximalen 10-12 $, wären noch immer 500%

Strong buy

JS200

[js200]

Inverser HAMMER = es geht nach oben !!!!

Strong buy

JS200

[js200]

Sieht sehr gut aus, mit guten Umsätzen nach oben, keine zu hohe Orders ist OK.

JS200

[js200]

Info von heute

PR Newswire, 12/06/2001 08:01

IntraBiotics Completes Patient Enrollment in Phase III Study of Iseganan To Reduce Oral Mucositis
/FROM PR NEWSWIRE SAN FRANCISCO 415-543-7800/ [STK] IBPI [IN] BIO MTC [SU] PER TO BUSINESS AND MEDICAL EDITORS:

IntraBiotics Completes Patient Enrollment in Phase III Study of Iseganan To

Reduce Oral Mucositis
MOUNTAIN VIEW, Calif., Dec. 6 /PRNewswire/ -- IntraBiotics Pharmaceuticals, Inc. (NASDAQ:IBPI), a biopharmaceutical company engaged in the development of novel antibiotics, today announced that it has completed patient enrollment in the second of three planned pivotal Phase III trials of its iseganan HCl antibiotic to reduce the severity of oral mucositis, a painful and debilitating condition resulting from the treatment of cancer. Results of the first trial were announced in the second quarter of this year.

This second Phase III trial is designed to evaluate the safety and efficacy of iseganan HCl oral solution in reducing the severity of oral mucositis in patients receiving radiation therapy with and without concurrent chemotherapy to treat cancers of the head and neck. 544 patients were enrolled at 53 investigational sites in the United States, Canada and Europe. "Evidence is accumulating that oral microbes play a major role in oral mucositis. We are pleased to have rapidly enrolled this clinical trial. We are hopeful that a major advance in the care of our patients is coming soon," said Dr. Walter Curran of the Radiation Therapy Oncology Group (RTOG) of the American College of Radiology. The Company anticipates that results of this study will be available in the second quarter of 2002.

"This study is important as it is the largest randomized placebo controlled trial, both in the number of enrolled patients and participating investigational centers, that evaluates a product for the treatment of oral mucositis," stated Dr. Andy Trotti, co-chairman of the study`s steering committee, Program Leader and Director of Clinical Trials, Radiation Oncology at H. Lee Moffitt Cancer Center. "Currently, there is no effective treatment available for reducing oral mucositis and its associated pain and swallowing dysfunction. As more aggressive radiation and chemotherapy-radiation programs are developed to treat cancers of the head and neck, the side effects of the cancer treatments are also intensified, including oral mucositis. It has been a privilege to help develop a product to reduce the severity of this devastating side effect of cancer therapies."

The Company also recently announced the initiation of a Phase III trial of iseganan HCl oral rinse in patients undergoing high dose chemotherapy who are likely to experience oral mucositis. Oral mucositis resulting from chemotherapy and radiotherapy are quite similar. The chemotherapy trial is currently enrolling patients on schedule at approximately 30 sites in the United States. Full enrollment of all 500 patients and data analysis is expected to conclude in the fourth quarter of 2002. The three phase III trials are expected to form the basis for a new drug application for iseganan.

Oral mucositis is a frequent and debilitating side effect of cancer therapies characterized by sores and painful ulcers in the mouth. Radiation therapies and chemotherapy damage the cells that line the mouth, allowing bacteria and fungi normally found inside the mouth to invade tissue and cause infection. Cancer patients often identify oral mucositis as the single worst side effect of radiation therapy and chemotherapy, causing pain so severe as to prevent drinking, eating and sleeping. Often, patients receive nutrition through a feeding tube and fluids and narcotic painkillers intravenously due to this condition. In some cases interruption of cancer treatment is necessary.

Dr. Henry Fuchs, President and Chief Operating Officer of IntraBiotics commented, "We are committed to demonstrating iseganan oral solution`s safety and effectiveness in helping to lessen the severity of oral mucositis and its associated pain experienced by cancer patients. Having completed the radiotherapy trial, IntraBiotics will now seek to identify a licensing partner to help with the registration and commercialization of iseganan." Dr. Fuchs was also named to serve as a Director of the Company this past week.

JS200

[DieBesten]

@js200

Die Entwicklung sieht doch super aus.
Ich würde sagen STRONG BUY

Gruß DieBesten

[js200]

@Die Besten

Scheint einen Widerstand zu sein bei 2,2 --- 2,4 $,mit wenig Umsatz ist der schwer zu nehmen, nur mit Geduld !!!

Die ist bei mir vorhanden.

Wenn du mal Zeit hast, sieh dir SCIO ( SCIOS) mal an.

Strong buy

JS200

[Bizcom]

Return-Path: <[e-mail]>
Received: from mailout2.scurrier.com ([170.224.5.35]) by mailin03.sul.t-online.de
with smtp id 16E9GQ-1YwZ16C; Wed, 12 Dec 2001 14:17:34 +0100
Received: (qmail 10291 invoked by uid 113); 12 Dec 2001 13:14:57 -0000
Message-ID: <[e-mail]>
From: [e-mail]
Cc: recipient list not shown: ;
Broadcastjobid: 111321
Content-type: text/plain
Date: Wed, 12 Dec 2001 08:15:43 -0500
Subject: PAIN IS A SERIOUS COMPLICATION OF ORAL MUCOSITIS
X-OriginalArrivalTime: 12 Dec 2001 13:15:51.0906 (UTC) FILETIME=[1F7C1C20:01C1830F]





CONTACT:
Gary Titus
Sr. Director, Finance
IntraBiotics Pharmaceuticals, Inc.
[phone]


PAIN IS A SERIOUS COMPLICATION OF ORAL MUCOSITIS

ISEGANAN REDUCES ORAL PAIN ASSOCIATED WITH ORAL MUCOSITIS

ORLANDO, FL Tuesday, December 12, 2001 - IntraBiotics Pharmaceuticals, Inc. (Nasdaq: IBPI), a biopharmaceutical company engaged in the development of novel antibiotics, today announced results correlating pain with other clinical outcome measures obtained from their Phase III clinical trial of iseganan HCl oral rinse. Results were reported at a meeting of the American Society of Hematology by Francis Giles, Head of Developmental Therapeutics, Department of Leukemia, MD Anderson Cancer Center, Houston, Texas, "Oral mucositis is often reported by patients as the most debilitating side effect they experienced during their bone marrow transplant. Pain is so severe that narcotic therapy is usually insufficient for our patients. It is of critical importance to develop new drugs to manage oral mucositis and alleviate pain. Important to our search for new drugs is our ability to accurately and reliably characterize the pain that patients experience."

As part of the Phase III trial of iseganan previously reported at the last American Society of Clinical Oncology, patients were asked to characterize their pain using a scoring system adapted from the Brief Pain Inventory. Although this measure is a widely accepted scale for the measurement of pain symptoms in clinical trials, the accuracy and reliability of this measure had not been evaluated in patients undergoing bone marrow transplantation. Patients` self-reported symptoms are considered important in documenting tangible evidence of reduction in morbidity of their oral mucositis. The present study documented that the patients` reports of pain directly correlated with other, independent evidence of their disease, including oral mucositis severity and difficulty swallowing as assessed by their doctor and with their requirement for narcotic therapy. Iseganan reduced the proportion of patients whose experiences were so severe by 67%. The analysis points to the urgent need for a product to reduce the seve

rity of oral mucositis and associated symptoms of pain and difficulty swallowing since palliation of pain symptoms is sub optimal.

Dr. Henry Fuchs, President and COO of IntraBiotics commented, "We are excited to provide important scientific information which extends the understanding of pain measurement, its correlation to severity of disease, and the importance of patient reported symptoms during bone marrow transplants."

IntraBiotics is focused on development of iseganan HCl, a novel antimicrobial, and has recently completed enrollment of its second phase III trial to evaluate the safety and efficacy of iseganan HCl oral solution in reducing the severity of oral mucositis in patients receiving radiation therapy with and without concurrent chemotherapy to treat cancers of the head and neck. A third phase III trial is also underway to further evaluate iseganan in reducing the severity of oral mucositis in bone marrow and stem cell transplant patients.

Oral mucositis is a frequent and debilitating side effect of cancer therapies characterized by sores and painful ulcers in the mouth. Radiation therapies and chemotherapy damage the cells that line the mouth, allowing bacteria and fungi normally found inside the mouth to invade tissue and cause infection. Cancer patients often identify oral mucositis as the single worst side effect of radiation therapy and chemotherapy, causing pain so severe as to prevent drinking, eating and sleeping. Often, patients receive nutrition through a feeding tube and fluids and narcotic painkillers intravenously due to this condition. In some cases interruption of cancer treatment is necessary. By killing bacteria in the mouth as patients undergo cancer treatments, iseganan HCl Oral Rinse may reduce the severity of oral mucositis.

IntraBiotics Pharmaceuticals, Inc., founded in 1994, is a biopharmaceutical company engaged in the development of novel antibacterial and antifungal drugs for the treatment and prevention of serious infectious diseases, including those caused by multi-drug resistant pathogens. IntraBiotics` product portfolio includes iseganan HCl oral solution for ventilator-associated pneumonia, iseganan aerosol for cystic fibrosis lung infections and ramoplanin topical for staphylococcal infections. Additional information is available at the Company`s web site. www.intrabiotics.com.



-------------------------------------------------------------------------
To unsubscribe click here
http://www.shareholder.com/visitors/unsubscribe.cfm?companyI…
-------------------------------------------------------------------------
Service provided by Shareholder.com.

[DieBesten]

Wenn die 2,40 $ auf Schlusskursbasis halten
dann sind wir mit einem Satz auf mind. 3$.

Strong buy and good trades

DieBesten

[DieBesten]

2,30$ ist ne harte Nuss!
So langsam müsste es doch mal knack machen.

Gruß DieBesten

[DieBesten]

@all
Super Umsatz in USA heute.
Da wird sich in den nächsten Tagen noch einiges tun.

Strong Buy

Gruß DieBesten

[Donkosak]

Mal zur Abwechslung was anderes als Sprüche wie weit die Aktie noch steigen mag


Iseganan Safely Reduced Oral Microflora in Mechanically Ventilated Patients

Approach Has Potential to Prevent Pneumonia

CHICAGO, Dec. 18 /PRNewswire/ -- IntraBiotics Pharmaceuticals, Inc. (Nasdaq: IBPI - news), a biopharmaceutical company engaged in the development of novel antibiotics announced the presentation of data from a positive Phase IIa clinical study of its antibiotic, iseganan hydrochloride oral solution. The purpose of this study was to evaluate the potential of iseganan to safely reduce oral bacteria as a potential approach to prevent ventilator-associated pneumonia (VAP). The data was presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago and has been presented at the European Society of Intensive Care Medicine.

``This trial is exciting because we desperately need a new antibiotic to prevent this devastating infection in hospital patients who are mechanically-ventilated to help them breathe,`` said Dr. Marin Kollef, Associate Professor of Medicine at the Washington University School of Medicine and Director of Medical Critical Care and Respiratory Care Services at Barnes-Jewish Hospital, St. Louis, Missouri. Approximately 740,000 patients are placed on ventilators in the United States each year. Because these patients have ventilator tubes in their mouths and throats, microorganisms in their saliva can be aspirated into the lungs and cause pneumonia. Of those patients who remain on mechanical ventilation for more 5 days, 15% or more are expected to develop ventilator-associated pneumonia (VAP). There presently are no antimicrobial therapies approved for the prevention of VAP.

Dr. Kollef presented results from this multicenter, double-blind placebo-controlled trial. The results showed that iseganan was well tolerated and demonstrated significant reductions in the mean numbers of oral microorganisms in mechanically ventilated patients. The first dose of each day resulted in an immediate decrease in the mean oral microbial burden of 1 log for patients treated with iseganan compared to 0.1 log for patients receiving placebo (highly statistically significant results with p=0.01). This represents a relative reduction in microbial counts 10 times greater in patients receiving iseganan compared to placebo. Continued dosing with iseganan, six times daily, over 5 days resulted in a cumulative decrease of 3.2 log of bacteria in iseganan patients compared to a decrease of 0.9 log in placebo patients. This represents a relative reduction in the number of bacteria 100 times greater in patients receiving iseganan compared to placebo.

Dr. Kollef provided the following perspective for these results, ``Iseganan is a promising new antimicrobial with attractive properties for ventilated patients in the intensive care unit (ICU) to prevent pneumonia. One of the biggest concerns with antibiotic use in the ICU is the potential for antibiotic resistance which limits antibiotic treatment options. Over 30 clinical trials have demonstrated that certain combinations of currently available antibiotics reduce VAP, however these traditional antibiotics are not used in this country out of fear of bacterial resistance. Because iseganan is novel, fast acting, broad spectrum, a topical application, and does not get into the bloodstream, it alleviates much of this fear.``

Henry J. Fuchs, President and COO of IntraBiotics commented, ``We are pleased that iseganan shows promise as an agent for the prevention of ventilator-associated pneumonia. The results of this phase IIa study, demonstrating significant reductions in the oral microflora while being well tolerated, are consistent with similar studies completed in cancer patients. The lead indication for this same drug, iseganan HCl oral solution, is the prevention of oral mucositis associated with anti-cancer therapies. Iseganan is currently in Phase III trials in patients receiving radiotherapy for head and neck cancers for the prevention of oral mucositis with results expected in June, 2002 and in patients receiving stomatotoxic chemotherapy for bone marrow transplant with results expected in December, 2002. IntraBiotics is currently planning a pivotal trial to test iseganan for the prevention of VAP as the second indication for the product but no definitive start has been determined.``

Schönen Abend noch
Euer Donkosak-Grischka

[DieBesten]

@donkosak
Kann ich auch

IntraBiotics Presents Iseganan Phase IIa Data At ICAAC
Iseganan Safely Reduced Oral Microflora In Mechanically Ventilated Patients
Approach Has Potential To Prevent Pneumonia
Chicago, December 18, 2001- IntraBiotics Pharmaceuticals, Inc. (Nasdaq: IBPI), a biopharmaceutical company engaged in the development of novel antibiotics announced the presentation of data from a positive Phase IIa clinical study of its antibiotic, iseganan hydrochloride oral solution. The purpose of this study was to evaluate the potential of iseganan to safely reduce oral bacteria as a potential approach to prevent ventilator-associated pneumonia (VAP). The data was presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago and has been presented at the European Society of Intensive Care Medicine.

"This trial is exciting because we desperately need a new antibiotic to prevent this devastating infection in hospital patients who are mechanically-ventilated to help them breathe," said Dr. Marin Kollef, Associate Professor of Medicine at the Washington University School of Medicine and Director of Medical Critical Care and Respiratory Care Services at Barnes-Jewish Hospital, St. Louis, Missouri. Approximately 740,000 patients are placed on ventilators in the United States each year. Because these patients have ventilator tubes in their mouths and throats, microorganisms in their saliva can be aspirated into the lungs and cause pneumonia. Of those patients who remain on mechanical ventilation for more 5 days, 15% or more are expected to develop ventilator-associated pneumonia (VAP). There presently are no antimicrobial therapies approved for the prevention of VAP.

Dr. Kollef presented results from this multicenter, double-blind placebo-controlled trial. The results showed that iseganan was well tolerated and demonstrated significant reductions in the mean numbers of oral microorganisms in mechanically ventilated patients. The first dose of each day resulted in an immediate decrease in the mean oral microbial burden of 1 log for patients treated with iseganan compared to 0.1 log for patients receiving placebo (highly statistically significant results with p=0.01). This represents a relative reduction in microbial counts 10 times greater in patients receiving iseganan compared to placebo. Continued dosing with iseganan, six times daily, over 5 days resulted in a cumulative decrease of 3.2 log of bacteria in iseganan patients compared to a decrease of 0.9 log in placebo patients. This represents a relative reduction in the number of bacteria 100 times greater in patients receiving iseganan compared to placebo.

Dr. Kollef provided the following perspective for these results, "Iseganan is a promising new antimicrobial with attractive properties for ventilated patients in the intensive care unit (ICU) to prevent pneumonia. One of the biggest concerns with antibiotic use in the ICU is the potential for antibiotic resistance which limits antibiotic treatment options. Over 30 clinical trials have demonstrated that certain combinations of currently available antibiotics reduce VAP, however these traditional antibiotics are not used in this country out of fear of bacterial resistance. Because iseganan is novel, fast acting, broad spectrum, a topical application, and does not get into the bloodstream, it alleviates much of this fear."

Henry J. Fuchs, President and COO of IntraBiotics commented, "We are pleased that iseganan shows promise as an agent for the prevention of ventilator-associated pneumonia. The results of this phase IIa study, demonstrating significant reductions in the oral microflora while being well tolerated, are consistent with similar studies completed in cancer patients. The lead indication for this same drug, iseganan HCl oral solution, is the prevention of oral mucositis associated with anti-cancer therapies. Iseganan is currently in Phase III trials in patients receiving radiotherapy for head and neck cancers for the prevention of oral mucositis with results expected in June, 2002 and in patients receiving stomatotoxic chemotherapy for bone marrow transplant with results expected in December, 2002. IntraBiotics is currently planning a pivotal trial to test iseganan for the prevention of VAP as the second indication for the product but no definitive start has been determined."

IntraBiotics Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development of novel antibiotics for the treatment and prevention of serious infectious diseases, including those caused by multi-drug resistant pathogens. Additional information is available at the Company`s web site: www.intrabiotics.com.

Certain statements in this press release contain forward-looking information and are subject to risks and uncertainties, such as statements regarding product development, clinical developments and projections of future expenses. As such, they are subject to the occurrence of many events outside of IntraBiotics` control and are subject to various risk factors that could cause IntraBiotics` results to differ materially from those expressed in any forward-looking statement. The risk factors include, without limitation, the inherent risks of product development failure; uncertainty of the timing, cost, extent and results of clinical trials; risk of delays in conducting clinical trials due to factors such as slower than expected rate of patient recruitment, additional regulatory requests, inability to manufacture sufficient quantities of materials used for clinical trials, difficulties with clinical supplies or unforeseen safety issues; the Company`s ability to raise capital through private or public financings when needed or on favorable terms; regulatory risks, and risks related to proprietary rights, market acceptance and competition. These risk factors are more fully described in documents on file with the Securities and Exchange Commission including, but not limited to, our Annual Report on Form 10-K, as amended, for the year ended December 31, 2000 and on Form 10-Q, for the quarter ended September 30, 2001.

Copyright © 2000 by IntraBiotics Pharmaceuticals, Inc.
All rights reserved.

[Donkosak]

@Die Besten

Dein Humor ist einzigartig. Wäre nett wenn Du nur den wichtigen Teil der Meldung das nächstemal reinstellst. Was IBPI angeht sind wir glaube ich alle Profis

Donkosak Grischka

[DieBesten]

Oder in Deutsch

IntraBiotics Stellt PhasenIIa Iseganan Daten An ICAAC
Iseganan Verringerte Sicher MundcMikroflora Bei Mechanisch Gelüfteten Patienten
Annäherung Hat Potential, Pneumonie Zu verhindern
Chicago, Dezember 18, 2001- IntraBiotics Pharmaceuticals, Inc. (Nasdaq: IBPI), verkündete eine biopharmaceutical Firma, die an der Entwicklung der Romanantibiotika teilnahm, die Darstellung von Daten von einer klinischen Studie IIa der positiven Phase seiner Mundlösung des antibiotischen, iseganan Hydrochlorids. Der Zweck dieser Studie war, das Potential von iseganan auszuwerten, Mundbakterium als mögliche Annäherung sicher zu verringern, um Entlüfter-dazugehörige Pneumonie (VAP) zu verhindern. Die Daten wurden bei der Konferenz Interscience auf antibiotischen Mitteln und Chemotherapie (ICAAC) in Chicago dargestellt und sind an der europäischen Gesellschaft der intensiven Obachtmedizin dargestellt worden.

"dieser Versuch ist aufregend, weil wir hoffnungslos ein neues Antibiotikum benötigen, diese verheerende Infektion bei Krankenhauspatienten zu verhindern, die mechanisch-gelüftet werden, um ihnen zu helfen zu atmen," sagten Dr. Marin Kollef, Teilnehmerprofessor von Medizin an der Washingtonhochschulschule von Medizin und Direktor der medizinischen kritischen Obacht und der Atmungsobachtdienstleistungen am Barnes-Jüdischen Krankenhaus, St. Louis, Missouri. Ungefähr 740.000 Patienten werden auf Entlüfter in die Vereinigten Staaten jedes Jahr gelegt. Weil diese Patienten Entlüfterschläuche in ihren Öffnungen und Kehlen haben, können Mikroorganismen in ihrem Speichel in die Lungen und die Ursachenpneumonie angesogen werden. Von jenen Patienten, die auf mechanischer Ventilation für mehr 5 Tage bleiben, werden 15% oder mehr erwartet, um Entlüfter-dazugehörige Pneumonie (VAP) zu entwickeln. Es gibt momentan keine antibiotischen Therapien, die für die Verhinderung von VAP genehmigt werden.

Dr. Kollef stellte Resultate von diesem Multicenter, double-blind Placebo-kontrollierten Versuch dar. Die Resultate zeigten, die iseganan gut zugelassen wurde und zeigten bedeutende Verringerungen der Mittelzahlen Mundmikroorganismen bei mechanisch gelüfteten Patienten. Die erste Dosis jedes Tages ergab eine sofortige Abnahme an der Mittelmundmikrobenbelastung von 1 Maschinenbordbuch für die Patienten, die mit iseganan verglichen mit 0,1 Maschinenbordbuch für die Patienten behandelt wurden, die Placebo empfangen (in hohem Grade statistisch bedeutende Resultate mit p=0.01). Dieses stellt eine relative Verringerung der Mikrobenzählimpulse 10mal dar, die bei den Patienten grösser sind, die iseganan verglichen mit Placebo empfangen. Anhaltendes mit iseganan, sechsmal, über 5 Tagen täglich dosieren ergab eine kumulative Abnahme von Maschinenbordbuch 3,2 des Bakteriums bei den iseganan Patienten, die mit einer Abnahme von 0,9 Maschinenbordbuch bei Placebopatienten verglichen wurden. Dieses stellt eine relative Verringerung der Zahl Bakterium 100mal dar, die bei den Patienten grösser sind, die iseganan verglichen mit Placebo empfangen.

Dr. Kollef stellte die folgende Perspektive für diese Resultate zur Verfügung, "Iseganan ist ein vielversprechendes neues antibiotisches mit attraktiven Eigenschaften für gelüftete Patienten in der Maßeinheit der intensiven Obacht (ICU) zum Verhindern von Pneumonie. Eins der größten Interessen auf antibiotischen Gebrauch im ICU ist das Potential für antibiotischen Widerstand, der antibiotische Behandlungwahlen begrenzt. Über 30 klinischen Versuchen haben gezeigt, daß bestimmte Kombinationen der zur Zeit verfügbaren Antibiotika VAP verringern, gleichwohl diese traditionellen Antibiotika nicht in diesem Land aus Furcht vor bakteriellem Widerstand heraus benutzt werden. Weil Roman, schnelles fungierendes, ausgedehntes Spektrum, eine aktuelle Anwendung iseganan ist und nicht in den Blutstrom erhält, vermindert er viel dieser Furcht.",

Henry J. Fuchs, Präsident und COO von IntraBiotics kommentierte, "wir sind erfreut daß iseganan Erscheinenversprechung als Mittel für die Verhinderung der Entlüfter-dazugehörigen Pneumonie. Die Resultate dieser Phase IIa studieren und demonstrieren bedeutende Verringerungen der Mundmikroflora, beim gut zugelassen werden, sind gleichbleibend mit den ähnlichen Studien, die bei Krebspatienten durchgeführt werden. Die Leitunganzeige für diese gleiche Droge, iseganan Mundlösung HCl, ist die Verhinderung von Mundmucositis dazugehörig mit krebsbekämpfenden Therapien. Iseganan ist z.Z. in den Versuchen der Phase III bei den Patienten, die Strahlentherapie für Kopf- und Ansatzkrebse für die Verhinderung von Mundmucositis mit den Resultaten empfangen, die im Juni, 2002 und bei den Patienten erwartet werden, die stomatotoxic Chemotherapie für Knochenmarktransplant mit den Resultaten empfangen, die im Dezember, 2002 erwartet werden. IntraBiotics plant z.Z. einen Angelversuch, um iseganan auf die Verhinderung von VAP als die zweite Anzeige zu prüfen für das Produkt, aber kein endgültiger Anfang ist festgestellt worden.",

IntraBiotics Pharmaceuticals, Inc. ist eine biopharmaceutical Firma, die an der Entwicklung der Romanantibiotika für die Behandlung und die Verhinderung der ernsten ansteckenden Krankheiten, einschließlich deren teilnimmt, die durch beständige Krankheitserreger der Multidroge verursacht werden. Zusätzliche Informationen sind an der Web site der Firma vorhanden: www.intrabiotics.com.

Bestimmte Aussagen in diesem Pressekommuniqué enthalten das Vorwärts-Schauen von Informationen und sind abhängig von Gefahren und Ungewißheiten, wie Aussagen betreffend sind Produktentwicklung, klinische Entwicklungen und Projektionen der zukünftigen Unkosten. Als solcher, sind sie abhängig von dem Auftreten vieler Fälle außerhalb der Steuerung IntraBiotics` und sind abhängig von verschiedenen Gefahrenfaktoren, die Resultate IntraBiotics` veranlassen konnten, sich von denen materiell zu unterscheiden, die in jeder möglicher Vorwärts-schauenden Aussage ausgedrückt wurden. Die Gefahrenfaktoren umfassen, ohne Beschränkung, die zugehörigen Gefahren des Produktentwicklungsausfalls; Ungewißheit des TIMINGS, der Kosten, des Umfangs und der Resultate einer klinischen Versuche; Gefahr von verzögert, wenn sie die klinischen Versuche wegen der Faktoren wie langsam als erwartete Rate der geduldigen Verstärkung, der zusätzlichen regelnden Anträge, der Unfähigkeit, genügende Quantitäten Materialien herzustellen leitet, die für klinische Versuche benutzt werden, der Schwierigkeiten mit klinischen Versorgungsmaterialien oder der unvorhergesehenen Sicherheitsausgaben; die Fähigkeit der Firma, Kapital durch die privaten oder allgemeinen Finanzierungen, wenn erforderlich oder auf vorteilhafte Bezeichnungen anzuheben; regelnde Gefahren und Gefahren bezogen auf eigenen Rechten, Marktannahme und Konkurrenz. Diese Gefahrenfaktoren werden völlig in den Dokumenten auf Akte mit den Aktien und Austauschkommission einschließlich beschrieben, aber begrenzt nicht auf, unser jährlicher Bericht über Form 10-K, wie geändert worden, für das Jahr beendet Dezember 31, 2000 und über Form 10-Q, denn das beendete Viertel September 30, 2001.

Copyright© 2000 durch IntraBiotics Pharmaceuticals, Inc..
Alle Rechte vorbehalten.

[js200]

@die Besten

Heute 2,25 $

Morgen schaffen wir den Widerstand bei 2,3 und dann gehts hoch, Ziel 3,5 $ auf kurzem Zeithorizont.

Hatte den Widerstand zwischen 2,2 und 2,4 am 06.12.01 schon einmal angedeutet, mir scheint als würde dieser Morgen gebrochen, sollten die Umsätze in dieser Form anhalten.
6 bis 8x höher als sonst.

STRONG BUY und hoch mit der Kleine BIO

PS.: Wenn du mal Zeit hast schau mal BB:ENDV läuft GUUUT!!!

JS200

[Donkosak]

Hallo an Alle

Und nun nochmal was zum Mechanismus!

Novel Mechanism of Iseganan HCL Presented at ICAAC
IntraBiotics Presents Microbiology Data on Iseganan Aerosol for Treatment Of Respiratory Infections
CHICAGO, Dec. 19 /PRNewswire/ -- IntraBiotics Pharmaceuticals, Inc. (Nasdaq: IBPI - news), a biopharmaceutical company engaged in the development of novel antibiotics, yesterday announced new data on its lead compound iseganan HCl at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Robert I. Lehrer, M.D., Professor of Medicine at the University of California at Los Angeles School of Medicine, presented data on the novel mechanism by which iseganan, also known as protegrin IB-367, kills bacteria. Dr. Lehrer is a co-discoverer of protegrins and has studied their mechanism since 1993 and actively consults for IntraBiotics in this field.

Dr. Lehrer presented biophysical data as well as electron microscopic pictures of iseganan`s killing of bacteria, both a gram-positive species (S. aureus) and a gram-negative species (E. coli). Dr. Lehrer summarized iseganan`s mechanism of kill as ``hydro-osmotic trans-tesseral extrusion and rupture, or HOTTER. In other words, iseganan rapidly forms channels in the bacterial membrane, creating a severe imbalance in osmotic forces that lead to explosions of the membrane. The studies show that iseganan kill microbes through a dramatic and irreversible process within minutes. Furthermore, iseganan kills both gram-negative and gram-positive bacteria. No commercially-available antibiotic uses this mechanism to our knowledge.``

Henry J. Fuchs, M.D., IntraBiotics` President and Chief Operating Officer, said, ``This work is a vivid demonstration of how rapidly and effectively iseganan kills bacteria, properties that make it well-suited for our three intended indications for iseganan, namely prevention of oral mucositis, prevention of ventilator-associated pneumonia and treatment of lung infections in patients with cystic fibrosis. Each of these diseases calls for a broad-spectrum, fast-acting antibiotic that does not result in bacterial resistance. We are currently in Phase III trials for iseganan HCl oral solution for the prevention of oral mucositis, with results expected next June.`` Oral mucositis is a potentially devastating side effect of anti-cancer therapies that causes painful and infected ulcers in the mouth and for which there is no approved therapy.

Dr Fuchs also noted: ``Dr. Lehrer`s investigations of iseganan HCl have been invaluable in expanding our understanding of how this novel antimicrobial agent may be used to benefit patients for a variety of diseases, including oral mucositis. We are grateful for his long-term support and commitment to the development of this new class of antibiotic and of IntraBiotics.``

IntraBiotics also presented at ICAAC microbiological data demonstrating the potency of iseganan HCl against respiratory pathogens from patients with cystic fibrosis (CF). In laboratory studies, iseganan HCl was more potent or comparable relative to traditional antibiotics in inhibiting all but one of 291 pathogenic isolates obtained from the lungs of 40 CF patients who had participated in an earlier Phase I trial. There was no cross-resistance between iseganan and the other antibiotics tested, and no development of resistance.

Iseganan was the only agent tested that inhibited all strains of P. aeruginosa (n=222) at concentrations of 32 microgram per milliliter or less. Other traditional antibiotics tested against this organism included tobramycin, colistimethate, ceftazidime, and ciprofloxacin. Iseganan inhibited 90% of the P. aeruginosa strains at the same concentration as tobramycin and at a lower concentration than ceftazidime.

Bonnie Ramsey, M.D., Director of the Therapeutics Development Network of the Cystic Fibrosis Foundation, Professor of Pediatrics at the University of Washington and Director of the Pediatric General Clinical Research Center at the Children`s Hospital and Regional Medical Center of Seattle, commented on these results. ``In the laboratory, iseganan HCl has demonstrated the ability to quickly kill both gram-positive and gram-negative bacteria and has shown little evidence for engendering resistance. If successful, it could become a valuable new treatment in the battle to treat infections in patients with cystic fibrosis. The Therapeutics Development Network of the Cystic Fibrosis Foundation supports further study of iseganan hydrochloride aerosol for treatment of respiratory infection associated with cystic fibrosis in a Phase IIa trial.``

Dr. Fuchs described the status of this program: ``Iseganan HCl aerosol for the treatment of respiratory infections represents the third potential indication for our novel antibiotic. We are designing a Phase IIa trial for CF infections but no start date has been determined. We would also like to reiterate our thanks and gratitude for the support and encouragement of the Therapeutics Development Network and the Cystic Fibrosis Foundation in this regard.``

Bis dann Donkosak

PS:Was für ein Start heute

[Donkosak]

Hallo an Alle

Und nun nochmal was zum Mechanismus!

Novel Mechanism of Iseganan HCL Presented at ICAAC
IntraBiotics Presents Microbiology Data on Iseganan Aerosol for Treatment Of Respiratory Infections
CHICAGO, Dec. 19 /PRNewswire/ -- IntraBiotics Pharmaceuticals, Inc. (Nasdaq: IBPI - news), a biopharmaceutical company engaged in the development of novel antibiotics, yesterday announced new data on its lead compound iseganan HCl at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Robert I. Lehrer, M.D., Professor of Medicine at the University of California at Los Angeles School of Medicine, presented data on the novel mechanism by which iseganan, also known as protegrin IB-367, kills bacteria. Dr. Lehrer is a co-discoverer of protegrins and has studied their mechanism since 1993 and actively consults for IntraBiotics in this field.

Dr. Lehrer presented biophysical data as well as electron microscopic pictures of iseganan`s killing of bacteria, both a gram-positive species (S. aureus) and a gram-negative species (E. coli). Dr. Lehrer summarized iseganan`s mechanism of kill as ``hydro-osmotic trans-tesseral extrusion and rupture, or HOTTER. In other words, iseganan rapidly forms channels in the bacterial membrane, creating a severe imbalance in osmotic forces that lead to explosions of the membrane. The studies show that iseganan kill microbes through a dramatic and irreversible process within minutes. Furthermore, iseganan kills both gram-negative and gram-positive bacteria. No commercially-available antibiotic uses this mechanism to our knowledge.``

Henry J. Fuchs, M.D., IntraBiotics` President and Chief Operating Officer, said, ``This work is a vivid demonstration of how rapidly and effectively iseganan kills bacteria, properties that make it well-suited for our three intended indications for iseganan, namely prevention of oral mucositis, prevention of ventilator-associated pneumonia and treatment of lung infections in patients with cystic fibrosis. Each of these diseases calls for a broad-spectrum, fast-acting antibiotic that does not result in bacterial resistance. We are currently in Phase III trials for iseganan HCl oral solution for the prevention of oral mucositis, with results expected next June.`` Oral mucositis is a potentially devastating side effect of anti-cancer therapies that causes painful and infected ulcers in the mouth and for which there is no approved therapy.

Dr Fuchs also noted: ``Dr. Lehrer`s investigations of iseganan HCl have been invaluable in expanding our understanding of how this novel antimicrobial agent may be used to benefit patients for a variety of diseases, including oral mucositis. We are grateful for his long-term support and commitment to the development of this new class of antibiotic and of IntraBiotics.``

IntraBiotics also presented at ICAAC microbiological data demonstrating the potency of iseganan HCl against respiratory pathogens from patients with cystic fibrosis (CF). In laboratory studies, iseganan HCl was more potent or comparable relative to traditional antibiotics in inhibiting all but one of 291 pathogenic isolates obtained from the lungs of 40 CF patients who had participated in an earlier Phase I trial. There was no cross-resistance between iseganan and the other antibiotics tested, and no development of resistance.

Iseganan was the only agent tested that inhibited all strains of P. aeruginosa (n=222) at concentrations of 32 microgram per milliliter or less. Other traditional antibiotics tested against this organism included tobramycin, colistimethate, ceftazidime, and ciprofloxacin. Iseganan inhibited 90% of the P. aeruginosa strains at the same concentration as tobramycin and at a lower concentration than ceftazidime.

Bonnie Ramsey, M.D., Director of the Therapeutics Development Network of the Cystic Fibrosis Foundation, Professor of Pediatrics at the University of Washington and Director of the Pediatric General Clinical Research Center at the Children`s Hospital and Regional Medical Center of Seattle, commented on these results. ``In the laboratory, iseganan HCl has demonstrated the ability to quickly kill both gram-positive and gram-negative bacteria and has shown little evidence for engendering resistance. If successful, it could become a valuable new treatment in the battle to treat infections in patients with cystic fibrosis. The Therapeutics Development Network of the Cystic Fibrosis Foundation supports further study of iseganan hydrochloride aerosol for treatment of respiratory infection associated with cystic fibrosis in a Phase IIa trial.``

Dr. Fuchs described the status of this program: ``Iseganan HCl aerosol for the treatment of respiratory infections represents the third potential indication for our novel antibiotic. We are designing a Phase IIa trial for CF infections but no start date has been determined. We would also like to reiterate our thanks and gratitude for the support and encouragement of the Therapeutics Development Network and the Cystic Fibrosis Foundation in this regard.``

Bis dann Donkosak

PS:Was für ein Start heute

[DieBesten]

@js200
Der Wiederstand ist meiner Meinung nach geschafft.
Jetzt wird dein erstes Kursziel in Angriff genommen.
Sollte bei den Umsätzen einigermaßen zügig gehen.

Immer noch Strong buy

Gruß DieBesten

[js200]

Wiederstand scheint gebrochen !!!

Letzter Stand 22°°h 2,39 US $

Super HYPE am Anfang des heutigen Handels

Sieht top aus STRONG BUY

JS200

[JS222]

@die Besten

Kleinere Wiederstände:
2,8 $ bis 3,2 $ aus April und Mai 2001

Grössere Wiederstände bei 4,825 $ und 5,125 $ aus
Januar 2001 und April 2000, beim Durchbrechen dienen diese zur Unterstützung.

Strong buy

JS222

PS: JS222 ist der selbe wie JS200 nur mit einer anderen Mail Adresse im Ausland

[DieBesten]

Sieht doch super aus Heute

Rec. Time Action Price Volume Exch.
12:06:21 PM Trade (at Ask) 2.53 400 Nasdaq NM
12:06:21 PM Ask 2.53 100 Nasdaq NM
12:06:05 PM Ask 2.53 500 Nasdaq NM
12:05:51 PM Bid 2.49 100 Nasdaq NM
12:05:41 PM Ask 2.52 400 Nasdaq NM
12:05:16 PM Ask 2.53 500 Nasdaq NM
12:05:16 PM Trade (at Ask) 2.49 100 Nasdaq NM
12:05:11 PM Trade 2.46 100 Nasdaq NM
12:05:11 PM Ask 2.49 100 Nasdaq NM
12:05:00 PM Trade (at Ask) 2.46 500 Nasdaq NM
12:04:28 PM Bid 2.43 500 Nasdaq NM
12:04:25 PM Bid 2.43 100 Nasdaq NM
12:04:23 PM Bid 2.42 100 Nasdaq NM
12:04:18 PM Ask 2.46 100 Nasdaq NM
12:04:18 PM Trade (at Ask) 2.45 500 Nasdaq NM
12:04:18 PM Trade (at Ask) 2.45 400 Nasdaq NM
12:04:07 PM Trade (at Ask) 2.45 500 Nasdaq NM
12:04:07 PM Bid 2.41 200 Nasdaq NM
12:03:53 PM Ask 2.45 500 Nasdaq NM
12:03:45 PM Trade (at Ask) 2.45 1000 Nasdaq NM


Mal sehen wo wir Schließen?

[DieBesten]

Super entwicklung in USA

Rec. Time Action Price Volume Exch.
3:48:19 PM Ask 2.6 500 Nasdaq NM
3:48:04 PM Ask 2.6 200 Nasdaq NM
3:48:03 PM Trade (at Ask) 2.6 300 Nasdaq NM
3:48:03 PM Ask 2.6 500 Nasdaq NM
3:47:50 PM Ask 2.6 800 Nasdaq NM
3:47:34 PM Ask 2.6 500 Nasdaq NM
3:47:34 PM Ask 2.6 800 Nasdaq NM
3:47:33 PM Trade (at Ask) 2.6 300 Nasdaq NM
3:46:49 PM Ask 2.6 1100 Nasdaq NM
3:46:35 PM Ask 2.6 700 Nasdaq NM
3:46:35 PM Trade (at Ask) 2.6 400 Nasdaq NM
3:46:34 PM Ask 2.6 900 Nasdaq NM
3:46:34 PM Ask 2.6 1300 Nasdaq NM
3:46:33 PM Trade (at Ask) 2.6 200 Nasdaq NM
3:46:33 PM Ask 2.6 1500 Nasdaq NM
3:46:32 PM Bid 2.54 1800 Nasdaq NM
3:46:19 PM Ask 2.6 1700 Nasdaq NM
3:46:04 PM Ask 2.6 1400 Nasdaq NM
3:46:03 PM Trade (at Ask) 2.6 300 Nasdaq NM
3:46:03 PM Ask 2.6 1700 Nasdaq NM

[DieBesten]

Wenn das so weitergeht sehe ich mich gezwungen nochmal nachzukaufen.

Schlußkurs USA

Rec. Time Action Price Volume Exch.
4:00:36 PM Ask 3.1 400 Nasdaq NM
4:00:36 PM Bid 2.31 100 Nasdaq NM
4:00:36 PM Ask 3.1 100 Nasdaq NM
4:00:36 PM Bid 2.31 1800 Nasdaq NM
4:00:09 PM Ask 2.67 100 Nasdaq NM
4:00:05 PM Ask 2.67 200 Nasdaq NM
3:58:56 PM Ask 2.63 300 Nasdaq NM
3:58:56 PM Bid 2.54 1800 Nasdaq NM
3:58:56 PM Ask 2.63 300 Nasdaq NM
3:58:56 PM Bid 2.54 1800 Nasdaq NM
3:58:27 PM Ask 2.63 300 Nasdaq NM
3:58:27 PM Trade (at Ask) 2.63 300 Nasdaq NM

Schönes Wochenende

DieBesten

[JS222]

@die Besten

Schluss bei 2,63 ist sehr gut = + 8,23 %

Bei 2,80 $ nähern wir uns bei 100% Gewinn innerhalb 2 Monate.
Glaubst du wirklich daran, noch nachzukaufen ????
MACD --- OK
RSI ---- steht leicht unter Druck!!! bei 65-66
MOMENTUM ----OK
Sehr kleine Umsätze 200.000 St. ?????

Ich habe schon einen schönen Vorrat!!!!

Strong buy

JS222 / JS200

[DieBesten]

@JS222
Frohes und gesundes neues Jahr erst mal.

Habe heute noch mal nachgekauft um die Stücke für 4,5$ wieder zu verkaufen.
Bin guter dinge hoffentlich klappt es.


Gruß DieBesten

[Heitop]

An Die Besten
Warum bei ca. 4,5 $ schon verkaufen ??? In Deinem Posting vom 02.12.01 sollte der nächst größere Wiederstand erst
bei ca. 5,2-5,5 $ sein ! Und Dein 12 Monatsziel lag mM bei
10-12 $.

[DieBesten]

@Heitop
Meinte nur die Stücke die ich mir gestern zugelegt habe.
Mit den anderen bleibe ich natürlich long.

Gruß DieBesten

[DieBesten]

Letzter Trade und Schlußkurs in USA

3:57:07 PM Trade (at Ask) 2.8 10000 Nasdaq NM

Das läßt hoffen für nächste Woche
Vielleicht nehmen wir den Widerstand ja gleich am Montag.


Gruß und schönes Wochenende

DieBesten

[DieBesten]

IntraBiotics Ernennt Oberen Hauptleiter: Eric Bjerkholt, Älterer Vizepräsident Und Finanzleiter
MOUNTAIN VIEW, CA Januar 4, 2002 - IntraBiotics Pharmaceuticals, Inc. (Nasdaq: Als IBPI), eine biopharmaceutical Firma, die an der Entwicklung der Romanantibiotika teilnahm, heute verkündete die Verabredung von Eric Bjerkholt älterer Vizepräsident und Finanzleiter.

Dr. Henry Fuchs, Präsident und funktionierender Hauptoffizier von IntraBiotics kommentierte, "wir werden aufgeregt, um Eric der Managementmannschaft bei IntraBiotics hinzuzufügen. Als Eric holt eine Fülle der Erfahrung seinen Hintergrund im Investitionbankverkehr, ein Finanzleiter und seine neuere Erfahrung als Führer einer Firma gegeben.",

Eric Bjerkholt hat sieben Jahre Erfahrung im healthcare-Investitionbankverkehr. Früher Vizepräsident an JP Morgan, Eric ist für viel Billigkeit und andere Verhandlungen in die Biotechnologie-, pharmazeutischen und anderenhealthcaresektoren verantwortlich gewesen. Vor kurzem, ist Eric Gründer, CFO, Präsident und CEO von Nahrung LifeSpring, eine privat gehaltene nutraceutical Firma gewesen.

"ich werde durch die Gelegenheit, eine Firma auf seiner Weise zum Durchführen der klinischen Versuche der Phase III einer Romanbehandlung für Mundmucositis gut zu verbinden," kommentierter Herr Bjerkholt aufgeregt. "IntraBiotics poised auch, um iseganan für die zusätzlichen, wichtigen Anzeigen zu entwickeln. Die CFO-Rolle ist beim Versichern wichtig, daß Wert für Aktionäre wird verwirklicht durch unsere klinischen Entwicklungsprogramme.",

IntraBiotics Pharmaceuticals, Inc., gegründet 1994, ist eine biopharmaceutical Firma, die an der Entwicklung des Romanantibakteriellen Mittels und der pilzbefallverhütenden Drogen für die Behandlung und die Verhinderung der ernsten ansteckenden Krankheiten, einschließlich deren teilnimmt, die durch beständige Krankheitserreger der Multidroge verursacht werden. Produktmappe IntraBiotics` umfaßt iseganan Mundlösung HCl für Mundmucositis, für die Verhinderung der Entlüfter-dazugehörigen Pneumonie, iseganan Aerosol für cystic Fibrosislungenflügelinfektion und das ramoplanin, das für Staphylokokkeninfektion aktuell ist. Zusätzliche Informationen sind am Netzaufstellungsort www.intrabiotics.com der Firma vorhanden.

Bestimmte Aussagen in diesem Pressekommuniqué enthalten das Vorwärts-Schauen von Informationen und sind abhängig von Gefahren und Ungewißheiten, wie Aussagen betreffend sind Produktentwicklung, klinischen Entwicklungen und Projektionen der zukünftigen Unkosten. Als solcher, sind sie abhängig von dem Auftreten vieler Fälle außerhalb der Steuerung IntraBiotics` und sind abhängig von verschiedenen Gefahrenfaktoren, die Resultate IntraBiotics` veranlassen konnten, sich von denen materiell zu unterscheiden, die in jeder möglicher Vorwärts-schauenden Aussage ausgedrückt wurden.

Die Gefahrenfaktoren umfassen, ohne Beschränkung, die zugehörigen Gefahren des Produktentwicklungsausfalls; Ungewißheit des TIMINGS, der Kosten, des Umfangs und der Resultate einer klinischen Versuche; Gefahr von verzögert, wenn sie die klinischen Versuche wegen der Faktoren wie langsam als erwartete Rate der geduldigen Verstärkung, der zusätzlichen regelnden Anträge, der Unfähigkeit, genügende Quantitäten Materialien herzustellen leitet, die für klinische Versuche benutzt werden, der Schwierigkeiten mit klinischen Versorgungsmaterialien oder der unvorhergesehenen Sicherheitsausgaben; die Fähigkeit der Firma, Kapital durch die privaten oder allgemeinen Finanzierungen, wenn erforderlich oder auf vorteilhafte Bezeichnungen anzuheben; regelnde Gefahren und Gefahren bezogen auf eigenen Rechten, Marktannahme und Konkurrenz. Diese Gefahrenfaktoren werden völlig in den Dokumenten auf Akte mit die Aktien und Austauschkommission einschließlich beschrieben, aber begrenzt nicht auf, unser jährlicher Bericht über Form 10-K, wie geändert worden, für das Jahr beendet Dezember 31, 2000 und über Form 10-Q, denn das beendete Viertel September 30, 2001.

Copyright© 2000 durch IntraBiotics Pharmaceuticals, Inc..
Alle Rechte vorbehalten.

[kalabrienfan]

Habe heute für 3 Euro meine Teile verkauft.
Schöner Gewinn für die kurze Zeit. Bitte vergeßt bei aller
Euphorie nicht, daß die Finanzierung auf etwas wackligen
Beinen steht. Außerdem hat Förtsch die Aktie empfohlen, da
kann es ganz schnell runterpurzeln. Sieh Xoma. Vielleicht
lege ich sie mir wieder als Long-Position ins Depot, wenn
die Zulassung durch ist.
Viel Glück Euch allen noch.

[spekulativ]

@DieBesten
dann hast du ja letzte woche schon den richtigen richer gehabt.

Gruß spekulativ

[js200]

@die Besten

Die 2,8$ scheinen als Unterstützung zu helfen
Beim knacken des wiederstandes von 3,2$ ist der weg frei bis 4,8 ----- 5,2 $

Umsätze sind gefallen, müssten mal wieder anheben zwecks knacken des Wiederstandes.

Die 3,2$ Grenze ist auch die 200ter Tageslinie

Rechne mit leichten seitwärts gerichteten Kursen für die nächsten Tage.

Wie ist deine Meinung????

Strong buy

JS200

[Heitop]

Aus welchem Grund haben wir in den letzten Tagen so einen
geringen Handels Umsatz bei ibpi.Ist dieses nur mit dem schlechten Markt zur Zeit zu begründen?Oder war der Anstieg der letzten Wochen zu schnell ? Oder Oder ???

[puhvogel]

Ich finde, IBPI hat sich gegenüber vergleichbaren Biotechs ganz gut gehalten. PGNX hat zum Beispiel auch mal deutlich höhere Umsätze gesehen.

[js200]

IntraBiotics Pharmaceuticals, Inc. Announces $13.9 Million Private Placement Of Common Stock
30 Jan 2002, 08:03am ET
E-mail or Print this story
- - - - -
/FROM PR NEWSWIRE SAN FRANCISCO 415-543-7800/ [STK] IBPI [IN] BIO MTC [SU] TO BUSINESS AND MEDICAL EDITORS:

IntraBiotics Pharmaceuticals, Inc. Announces $13.9 Million Private Placement

Of Common Stock

MOUNTAIN VIEW, Calif., Jan. 30 /PRNewswire-FirstCall/ -- IntraBiotics Pharmaceuticals, Inc. (NASDAQ:IBPI) today announced that it has entered into definitive purchase agreements to sell 5.9 million shares of newly issued common stock in a private placement to selected institutional and private investors. The private placement is expected to raise net proceeds of approximately $13.9 million. Completion of the private placement is subject to customary closing conditions.

The securities sold in this private placement have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.


JS200

[Bocknase]

Wie lange wird der Aufwärtstrend bei IBPI anhalten? Stehen
wir erst am Anfang? Was bewegt den Kurs so nachhaltig nach
oben? Wer kann dazu etwas sagen?
Intra ist zur Zeit der einzige Biotechwert in meinem Depot,
der richtig Freude macht, hoffentlich noch recht lange !!
Charttechnisch sieht es doch nicht schlecht aus:



Sowohl die 38-Tagelinie als auch die 200-Tagelinie sind
klar nach oben durchbrochen. Jetzt muß nur noch die
Nasdaq in Fahrt kommen. Was meint Ihr?

[js200]

IntraBiotics Reports Fourth Quarter 2001 Financial and Operating Results
7 Feb 2002, 08:01am ET
E-mail or Print this story
- - - - -
/FROM PR NEWSWIRE SAN FRANCISCO 415-543-7800/ [STK] IBPI [IN] BIO MTC [SU] ERN TO BUSINESS AND MEDICAL EDITORS:

IntraBiotics Reports Fourth Quarter 2001 Financial and Operating Results

MOUNTAIN VIEW, Calif., Feb. 7 /PRNewswire-FirstCall/ -- IntraBiotics Pharmaceuticals, Inc. (NASDAQ:IBPI), a biopharmaceutical company engaged in the development of novel antibiotics, today reported financial results for the fourth quarter ended December 31, 2001.

IntraBiotics reported a net loss of $7.4 million, or $0.25 per basic and diluted share for the fourth quarter of 2001, compared with a net loss of $15.0 million, or $0.52 per basic and diluted share in the same period of 2000.

Dr. Henry Fuchs, president and chief operating officer of IntraBiotics, said, "I am very pleased with the progress we achieved in the fourth quarter and IntraBiotics ended 2001 on a positive note."

Dr. Fuchs said, "the highlights of the fourth quarter 2001 included completion of enrollment in a Phase III trial of iseganan HCl for the prevention of oral mucositis in patients undergoing radiation therapy for head and neck cancers. The Company also began enrollment in a second phase III trial of iseganan HCl for the prevention of oral mucositis in patients undergoing chemotherapy. These two trials are designed to demonstrate the safety and efficacy of iseganan HCl oral solution to reduce the incidence and severity of ulcerative oral mucositis in cancer patients, receiving high dose chemotherapy or radiotherapy for treatment of head and neck cancer."

Dr. Fuchs reiterated the company`s expectation that results from the radiotherapy trial will be announced in the second quarter of 2002 and that the results of the second chemotherapy trial will be announced in the fourth quarter of 2002.

Because the company`s product candidates are still in clinical development, IntraBiotics reported no product sales or contract revenues in the fourth quarter of 2001. The company reported total operating expenses of $7.7 million in the fourth quarter, compared with total operating expenses of $16.4 million in the comparable period of 2000.

Research and development expenses were $5.7 million in the fourth quarter of 2001 compared to $12.8 million in the fourth quarter of 2000, reflecting the effect of the company`s previously announced restructuring in May of 2001. General and administrative expenses were $2.0 million compared to $3.6 million in the comparable quarter of 2000. IntraBiotics had 31 full-time employees at December 31, 2001, down from 141 employees at year end 2000.

For the full year 2001, IntraBiotics reported a net loss of $67.4 million, or $2.29 per basic and diluted share, compared with a net loss of $45.6 million, or $2.02 per basic and diluted share in 2000. The loss for 2001 included restructuring and other charges of $22.0 million or $0.75 per share.

Total operating expenses for 2001 were $69.2 million compared with $50.7 million in 2000. Research and development expenses were $38.0 million compared with $39.2 million in 2000. General and administrative expenses were $9.2 million compared with $11.6 million in 2000.

The company also reported a total of $35.5 million in cash, cash equivalents, restricted cash and investments at December 31, 2001, a decrease of $5.7 million from the prior quarter, including restricted cash of $7.5 million. The Company also had outstanding debt of $9.4 million.

On February 1, 2002, the company closed a private placement of 5.9 million shares of common stock with net proceeds to the company of $13.9 million after expenses.

IntraBiotics Pharmaceuticals, Inc., founded in 1994, is a biopharmaceutical company engaged in the development of novel antibacterial and antifungal drugs for the prevention or treatment of serious diseases. Our clinical development programs focus on solving medical problems for patients who currently have few or no satisfactory alternatives. Additional information is available at the company`s website: www.intrabiotics.com.

Certain statements in this press release contain forward-looking information and are subject to risks and uncertainties, such as statements regarding product development, clinical developments and projections of future expenses. As such, they are subject to the occurrence of many events outside of IntraBiotics` control and are subject to various risk factors that could cause IntraBiotics` results to differ materially from those expressed in any forward-looking statement. The risk factors include, without limitation, the inherent risks of product development failure; uncertainty of the timing, cost, extent and results of clinical trials; risk of delays in conducting clinical trials due to factors such as slower than expected rate of patient recruitment, additional regulatory requests, inability to manufacture sufficient quantities of materials used for clinical trials, difficulties with clinical supplies or unforeseen safety issues; the company`s ability to raise capital through private or public financings when needed or on favorable terms; regulatory risks, and risks related to proprietary rights, market acceptance and competition. These risk factors are more fully described in documents on file with the Securities and Exchange Commission including, but not limited to, our Registration Statement on Form S-1 (No. 333-95461), Annual Report on Form 10-K for the fiscal year ended December 31, 2000 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2001.


INTRABIOTICS PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

(UNAUDITED)

THREE MONTHS ENDED FISCAL YEAR ENDED

DECEMBER 31, DECEMBER 31,

2001 2000 2001 2000

Operating expenses:

Research and development $5,652 $12,763 $38,034 $39,152

General and administrative 2,038 3,623 9,202 11,560

Restructuring and other

charges -- -- 21,956 --

Total operating

expenses 7,690 16,386 69,192 50,712

Operating loss (7,690) (16,386) (69,192) (50,712)

Interest income 315 1,560 2,843 5,699

Interest expense (156) (205) (1,110) (563)

Other income 93 -- 93 --

Net loss $(7,438) $(15,031) $(67,366) $(45,576)

Basic and diluted net

loss per share $(0.25) $(0.52) $(2.29) $(2.02)

Shares used to compute

basic and diluted net

loss per share 29,692 29,146 29,432 22,512

Proforma basic and diluted

net loss per share $(1.67)

Shares used to compute

proforma basic and diluted

net loss per share 27,231

Condensed Balance Sheet Data

(In thousands)

(Unaudited)

December 31, December 31,

2001 2000

Cash and cash equivalents, restricted cash

and short term investments $35,470 $86,065

Total assets $42,465 $108,288

Total stockholders` equity $26,321 $89,955

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X75875044

SOURCE IntraBiotics Pharmaceuticals, Inc.

-0- 02/07/2002

/CONTACT: Eric Bjerkholt, Sr. Vice President & CFO of IntraBiotics Pharmaceuticals, Inc., [phone]/

/Web site: http://www.intrabiotics.com/


JS200

[Bocknase]

IntraBiotics to Present at Lehman Brothers Global Healthcare Conference


MOUNTAIN VIEW, Calif., Feb. 26, 2002 - IntraBiotics Pharmaceuticals, Inc. (Nasdaq: IBPI), a biopharmaceutical company engaged in the development of novel antibiotics, today announced that Henry J. Fuchs, MD, the company`s president and chief operating officer, will present a general corporate update at the Lehman Brothers 5th Annual Global Healthcare Conference on Thursday, February 28 at 8:30 a.m. (ET) in the St. Augustine A Room at Disney`s Grand Floridian Resort & Spa in Orlando, Florida.

The IntraBiotics presentation will be available live by dialing 800-553-3587, identification number 1561222. International callers can listen to the presentation by dialing 303-713-7920, identification number 1561222. A replay of the presentation will be available Friday, March 1 through March 11. To access the replay, please dial 800-625-5288, identification number 1561222. International callers can access the replay by dialing 303-804-1855, identification number 1561222.

IntraBiotics Pharmaceuticals, Inc., founded in 1994, is a biopharmaceutical company engaged in the development of novel antibacterial and antifungal drugs for the prevention or treatment of serious diseases. Our clinical development programs focus on solving medical problems for patients who currently have few or no satisfactory alternatives. Additional information is available at the company`s website: www.intrabiotics.com.

Certain statements in this press release contain forward-looking information and are subject to risks and uncertainties, including the occurrence of many events outside of IntraBiotics` control, that could cause IntraBiotics` results to differ materially from those expressed in any forward-looking statement. These risk factors are more fully described in documents on file with the Securities and Exchange Commission including, but not limited to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2001.

[SunshineGerda]

INTRABIOTICS WKN 936085
US-Kürzel: IBPI
Kurs: 22 US-cents

Es tobt eine ÜBERNAHMESCHLACHT!

Der CEO Mario will 20 US-cents zahlen, dagegen hat bereits der größte Anteilseigner Protest eingelegt und bereits ein eigenes Angebot, welches 50% höher liegt ( somit ca. 30 US-cents ), auf den Tisch gelegt.

Das Unternehmen steht auf Allzeittief, nachdem ein Medikament nicht zugelassen wurde.
Dass jetzt aber diese Angebote für freie Aktionäre gemacht werden, dürfte eines zeigen:

Da steckt mehr Substanz hinter als viele glauben!!!

Die Aktie stand vor einem Jahr noch bei knapp 5$!!!

Der Chart:



Vor zwei Handelstagen ging es bereits bis auf 29 US-cents hoch bei SEHR HOHEN Umsätzen!!!

Am 3.4. kommt es zur nächsten Entscheidung: Alle News sind bei www.freerealtime.com nachzulesen!!! Einfach US-Kürzel eingeben und News anwählen!

Hier eine Übersicht:

Mar 31 2003
IntraBiotics Pharmaceuticals, Inc. Announces
Postponement of Stockholder Vote on Proposed
Financing
Mar 27 2003
Major Investor Votes No to Mario`s Insider Offer for
Intrabiotics Stock
Mar 20 2003
Major Investor Offers 50% More for Intrabiotics Shares
Than Mario`s Insider Group
Mar 5 2003
Mario`s Offer to Buy Intrabiotics Stock Is Unfair Says
Major Shareholder


Mein Tip:

Jetzt noch in DEUTSCHLAND unter US-KURS (!!!) kaufen - Taxe akt. nur 20 cents im ask!!! USA 22US-cents!

Das Übernahmeangebot dürfte am Ende mind. 50 US-cents betragen!!!

Nutzt diese Chance!

Sunshine!Gerda